(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cystic Fibrosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Cystic Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Cystic Fibrosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cystic Fibrosis Market.
The Cystic Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Cystic Fibrosis Pipeline Report:
- Companies across the globe are diligently working toward developing novel Cystic Fibrosis treatment therapies with a considerable amount of success over the years.
- Cystic Fibrosis companies working in the treatment market are Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceutical, AbbVie, Armata Pharmaceutical, 4D Molecular Therapeutics, Eloxx Pharmaceuticals, Verona Pharma, and others, are developing therapies for the Cystic Fibrosis treatment
- Emerging Cystic Fibrosis therapies such as – SP-101, LUNAR CF, KB407, VX-522, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, and others are expected to have a significant impact on the Cystic Fibrosis market in the coming years.
- In September 2021, Vertex Pharmaceuticals initiated a Phase III, randomized, double-blind, controlledstudy evaluating the efficacy and safety of VX-121 combination therapy in subjects with cystic fibrosis (cf) who areheterozygous for f508del and a minimal function mutation (F/MF). The purpose of this study is to evaluate the efficacyand safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are heterozygous forF508del and a minimal function mutation (F/MF participants).
- In November 2021, The Phase 2 clinical trial with ELX-02 in Class 1 cystic fibrosis (CF) patients with at least one G542X nonsense allele mutation saw encouraging topline results, according to Eloxx Pharmaceuticals. At the 1.5 mg/kg/day dose, ELX-02 was well tolerated and reduced sweat chloride in patients by a statistically significant 5.4 mmol/L
Cystic Fibrosis Overview
Cystic fibrosis (CF) is a recessive genetic disease caused by a mutation in the epithelial chloride channel—cystic fibrosistrans membrane conductance regulator (CFTR). CF is a predominant genetic disorder with a disease severity ranging from mild to life-threatening. The number of CF patients in a population varies depending on ethnicity
Get a Free Sample PDF Report to know more about Cystic Fibrosis Pipeline Therapeutic Assessment
Emerging Cystic Fibrosis Drugs Under Different Phases of Clinical Development Include:
- SP-101: Spirovant Sciences
- LUNAR CF: Arcturus Therapeutics
- KB407: Krystal Biotech
- OligoG: Algi Pharma
- MRT5005: Translate Bio
- CB280: Calithera Biosciences
- KB407 : Krystal Biotech
- VX-522: Vertex Pharmaceutical
- SPL84231: SpliSense
- Galicaftor/Navoc aftor/ABBV-576: AbbVie
- AP-PA02: Armata Pharmaceutical
- 4D-710: 4D Molecular Therapeutics
- ELX-02: Eloxx Pharmaceuticals
- Ensifentrine: Verona Pharma
Route of Administration
Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
Molecule Type
Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Cystic Fibrosis Pipeline Therapeutics Assessment
- Cystic Fibrosis Assessment by Product Type
- Cystic Fibrosis By Stage and Product Type
- Cystic Fibrosis Assessment by Route of Administration
- Cystic Fibrosis By Stage and Route of Administration
- Cystic Fibrosis Assessment by Molecule Type
- Cystic Fibrosis by Stage and Molecule Type
DelveInsight’s Cystic Fibrosis Report covers around 80+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Cystic Fibrosis product details are provided in the report. Download the Cystic Fibrosis pipeline report to learn more about the emerging Cystic Fibrosis therapies
Some of the key companies in the Cystic Fibrosis Therapeutics Market include:
Key companies developing therapies for Cystic Fibrosis are – Eloxx Pharmaceuticals, NovaBiotics, Arrowhead Pharmaceuticals, SolAeroMed, Translate Bio, Inc., Path BioAnalytics, Aridis Pharmaceuticals, Vertex Pharmaceuticals, AlgiPharma, Corbus Pharmaceuticals, Galapagos NV, Santhera Pharmaceuticals, Calithera Biosciences, Inc, AbbVie, Spyryx Biosciences, Inc., Verona Pharma, Laurent Pharmaceuticals Inc., Ligand Pharmaceuticals, Boehringer Ingelheim, OrPro Therapeutics, Protalix Biotherapeutics, Krystal Biotech, Insmed Incorporated, BiomX, Arcturus Therapeutics, and others.
Cystic Fibrosis Pipeline Analysis:
The Cystic Fibrosis pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Cystic Fibrosis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment.
- Cystic Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cystic Fibrosis drugs and therapies
Cystic Fibrosis Pipeline Market Drivers
- Rising incidence of Cystic Fibrosis, advance research and development over the last few years have contributed to get a clearer picture of the disease, and development of the healthcare industry are some of the important factors that are fueling the Cystic Fibrosis Market.
Cystic Fibrosis Pipeline Market Barriers
- However, no standard cure for cystic fibrosis, adverse effects associated with the drugs and other factors are creating obstacles in the Cystic Fibrosis Market growth.
Scope of Cystic Fibrosis Pipeline Drug Insight
- Coverage: Global
- Key Cystic Fibrosis Companies: Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceutical, AbbVie, Armata Pharmaceutical, 4D Molecular Therapeutics, Eloxx Pharmaceuticals, Verona Pharma, and others
- Key Cystic Fibrosis Therapies: SP-101, LUNAR CF, KB407, VX-522, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, and others
- Cystic Fibrosis Therapeutic Assessment: Cystic Fibrosis current marketed and Cystic Fibrosis emerging therapies
- Cystic Fibrosis Market Dynamics: Cystic Fibrosis market drivers and Cystic Fibrosis market barriers
Request for Sample PDF Report for Cystic Fibrosis Pipeline Assessment and clinical trials
Table of Contents
| 1 | Cystic Fibrosis Report Introduction |
| 2 | Cystic Fibrosis Executive Summary |
| 3 | Cystic Fibrosis Overview |
| 4 | Cystic Fibrosis- Analytical Perspective In-depth Commercial Assessment |
| 5 | Cystic Fibrosis Pipeline Therapeutics |
| 6 | Cystic Fibrosis Late Stage Products (Phase II/III) |
| 7 | Cystic Fibrosis Mid Stage Products (Phase II) |
| 8 | Cystic Fibrosis Early Stage Products (Phase I) |
| 9 | Cystic Fibrosis Preclinical Stage Products |
| 10 | Cystic Fibrosis Therapeutics Assessment |
| 11 | Cystic Fibrosis Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Cystic Fibrosis Key Companies |
| 14 | Cystic Fibrosis Key Products |
| 15 | Cystic Fibrosis Unmet Needs |
| 16 | Cystic Fibrosis Market Drivers and Barriers |
| 17 | Cystic Fibrosis Future Perspectives and Conclusion |
| 18 | Cystic Fibrosis Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Related Reports:
DelveInsight’s ‘Cystic Fibrosis-Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
DelveInsight’s ‘Cystic Fibrosis Epidemiology Forecast to 2032′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
DelveInsight’s “Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.
Vein Illumination Devices Market
DelveInsight’s “Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027” report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
DelveInsight’s “Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027” report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Latest Reports By DelveInsight
Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market | Alpha-Mannosidosis Market | Astigmatism Market | Autonomic Dysfunction Market | Chronic Gout Market | Corneal Ulcer Market | Hpv-Induced Cancers Market | Meningioma Market | Ocular Motility Disturbance Market | Stable Angina Market | Wilms Tumor Market
To know more about our Consulting Services, Click here: Healthcare Consulting
Recent Blog’s By DelveInsight:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187